Inositec AG ^Company

Inositec is a biotech company that develops a treatment for soft tissue calcification disorders based on its proprietary Inositune platform of inositol phosphate (IP6) analogs. Its lead programs address vascular and renal calcification disorders, including orphan indications. The company was founded in 2015 as a spin-off of ETH Zurich.